Abstract
BackgroundIn this study, we questioned efficacy of combination therapy of newly developed cancer vaccines for tumors refractory to immune checkpoint inhibitors (ICIs) and adoptive therapy of TCR-T cells. We have...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
